To the Editor Ms Swenson and colleagues1 reported findings from a retrospective analysis of the California Children’s Services paid claims data set for children with chronic illness. Their data illustrate the need for clinical, economic, and quality outcomes in patients with hemophilia. The authors seemed surprised by the fact that 0.4% of the cohort received 1 class of medications (antihemophilic factor) and accounted for 40.9% of total pharmacy expenditures.
Ruble JH, Brixner DI. Pharmacy Expenditures for Children With Serious Chronic Illness. JAMA. 2016;315(7):706. doi:10.1001/jama.2015.16978